Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 12/20 | 0.50 |
| ▸ | DRD2 | P14416 | 10/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809540 | 0.94 | ADRA1A (0.53) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809552 | 0.91 | ADRA1A (0.59) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809533 | 0.90 | ADRA1A (0.66) | ADRA1ADRD3DRD2DRD4GLA | |
| SCHEMBL13809560 | 0.88 | ADRA1A (0.55) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809547 | 0.88 | DRD3 (0.59) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809543 | 0.86 | DRD3 (0.60) | ADRA1ADRD3DRD2DRD4 | |
| SCHEMBL13809551 | 0.85 | ADRA1A (0.68) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809537 | 0.85 | ADRA1A (0.65) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL15580928 | 0.83 | ALDH1A1 (0.43) | ADRA1ADRD3DRD2DRD4GLA | |
| SCHEMBL13809558 | 0.83 | DRD3 (0.58) | ADRA1ADRD3DRD2DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | claimed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| EP-2714624-B1 | PROCESS FOR THE PREPARATION OF DEUTERATED COMPOUNDS CONTAINING N-ALKYL GROUPS | SANOFI SA (FR) | 2017-12-27 | — | — | EP | disclosed |
| EP-2714624-B1 | PROCESS FOR THE PREPARATION OF DEUTERATED COMPOUNDS CONTAINING N-ALKYL GROUPS | SANOFI SA (FR) | 2017-12-27 | — | — | EP | disclosed |
| US-9340489-B2 | Process for the preparation of deuterated compounds containing N-alkyl groups | SANOFI (FR) | 2016-05-17 | — | — | US | disclosed |
| US-20140081019-A1 | PROCESS FOR THE PREPARATION OF DEUTERATED COMPOUNDS CONTAINING N-ALKYL GROUPS | SANOFI (FR) | 2014-03-20 | — | — | US | disclosed |
| WO-2012160015-A1 | PROCESS FOR THE PREPARATION OF DEUTERATED COMPOUNDS CONTAINING N-ALKYL GROUPS | SANOFI (FR) | 2012-11-29 | — | — | WO | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1688412-A2 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRA1A 313/4885DRD3 1/4885DRD2 2/4885 |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRA1A 332/4885DRD3 1/4885DRD2 2/4885 |
| US-20140081019-A1 | PROCESS FOR THE PREPARATION OF DEUTERATED COMPOUNDS CONTAINING N-ALKYL GROUPS | HDHD5, DRD4, DRD2 | ADRA1A 158/4885DRD3 6/4885DRD2 3/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRA1A 313/4885DRD3 1/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.